Compare Stocks

Atalaya Mining Plc, together with its subsidiaries, engages in the mineral exploration and development in Spain. The company's flagship property is its 100% owned Proyecto Riotinto mine, an open-pit copper mine located in the Andalusia region of Spain. It produces copper concentrates, including silver by-products. The company was formerly known as EMED Mining Public Limited and changed its name to Atalaya Mining Plc in October 2015. Atalaya Mining Plc was incorporated in 2004 and is based in Nicosia, Cyprus.

BlackRock Defined Opportunity Credit Trust is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income, with a secondary objective of long-term capital appreciation. The Fund seeks to achieve its investment objectives by investing substantially all of its assets in loan and debt instruments, and loan-related and debt-related instruments (collectively credit securities). The Fund invests, at least 80% of its assets in any combination of various credit securities, such as senior secured floating rate and fixed rate loans; second lien or other subordinated or unsecured floating rate and fixed rate loans or debt; credit securities that are rated below investment grade by a nationally recognized credit rating organization or unrated securities that are deemed to be of comparable quality by the investment advisor, and investment grade corporate bonds. BlackRock Advisors, LLC is the investment advisor of the Fund.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.